Cancer-Myeloproliferative Neoplasms
| Title: | A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) |
| Description: | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea. |
| Drug/Procedure: | Ruxolitinib; Anagrelide; Placebo |
| NCT Number: | 03123588 |
| Notes: | Phase 2 |
| Start Date: | 10/24/17 |
| Status: | Recruiting |
| Principal Name: | Kerry Pulver, MD |
| Contact Name: | Olga Bittner, CCRC |
| Phone: | (208)367-7954 |